# Efficacy and Dose Ranging Study of Seroguard

> **NCT03660787** · PHASE2 · COMPLETED · sponsor: **Pharmasyntez** · enrollment: 114 (actual)

## Conditions studied

- Adhesion

## Interventions

- **DRUG:** Seroguard
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03660787
- **Lead sponsor:** Pharmasyntez
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-04
- **Primary completion:** 2018-01-23
- **Final completion:** 2018-01-23
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2019-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03660787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03660787, "Efficacy and Dose Ranging Study of Seroguard". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03660787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*